Drug class in one race
CD38 drugs for Multiple Myeloma
14 tracked CD38 drugs in the Multiple Myeloma race. The class explanation lives on the CD38 page; the full indication pipeline across every mechanism is on the Multiple Myeloma page.
2 approved / phase 47 Phase 33 Phase 1/22 Phase 1
Head-to-head evidence: BCD-264 vs CID-103 · BCD-264 vs CM313 · BCD-264 vs Daratumumab · BCD-264 vs Isatuximab · BCD-264 vs Mezagitamab · BCD-264 vs SAR442085